Abstracts tagged "Janus kinase (JAK)"

Abstract Number: 1277 • 2012 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: Year 2 Efficacy and Safety Results From a 24-Month Phase 3 Study
D. van der Heijde¹, Y. Tanaka², Roy Fleischmann³, Edward Keystone⁴, Joel M. Kremer⁵, C. Zerbini⁶, M. H. Cardiel⁷, S. B. Cohen⁸, P. T. Nash⁹, Y. Song¹⁰, D. Tegzova¹¹, B. Wyman¹², D. Gruben¹², B. Benda¹³, G. Wallenstein¹⁴, S. Krishnaswami¹², S. H. Zwillich¹², J. Bradley¹⁵, C. A. Connell¹⁶ and ORAL Scan Investigators¹⁷, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Metroplex Clinical Research Center, Dallas, TX, ⁴Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Toronto, ON, Canada, ⁵The Center for Rheumatology, Albany Medical College, Albany, NY, ⁶CEPIC – Centro Paulista de Investigação Clínica, São Paulo-SP, Sao Paulo, Brazil, ⁷Centro de Investigacion Clinica de Morelia, Morelia, Mexico, ⁸Metroplex Clinical Research Centre, Dallas, TX, ⁹Rheumatology Research Unit, Nambour Hospital, Sunshine Coast, Australia, ¹⁰Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ¹¹Institute of Rheumatology, Prague, Czech Republic, ¹²Pfizer Inc., Groton, CT, ¹³Clinical Development & Medical Affairs, Pfizer Inc., Collegeville, PA, ¹⁴Pfizer Inc, New York, NY, ¹⁵Worldwide Pharmaceutical Development, Pfizer Inc., Groton, CT, ¹⁶Pfizer Inc, Groton, CT, ¹⁷Groton
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This 24‑month (Mo) Phase 3…
Abstract Number: 1297 • 2012 ACR/ARHP Annual Meeting
Tofacitinib and Adalimumab Achieve Similar Rates of Low Disease Activity in Rheumatoid Arthritis — Lack of Improvement in Disease Activity Score by 3 Months Predicts Low Likelihood of Low Disease Activity At 1 Year
Ronald F. van Vollenhoven¹, Sriram Krishnaswami², Birgitta Benda³, David Gruben⁴, Bethanie Wilkinson⁴, Charles A. Mebus⁴, Samuel H. Zwillich² and John Bradley², ¹Karolinska Institute, Stockholm, Sweden, ²Pfizer Inc, Groton, CT, ³Pfizer Inc., Collegeville, PA, ⁴Pfizer Inc., Groton, CT
Background/Purpose: Tofacitinib is a novel oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This post-hoc analysis of the…
Abstract Number: 1322 • 2012 ACR/ARHP Annual Meeting
Coadministration of ASP015K, a Novel Janus Kinase Inhibitor with Methotrexate Demonstrates Tolerability and Lack of Pharmacokinetic Interactions in Patients with Rheumatoid Arthritis
Tong Zhu¹, Kazuo Oda², Udaya Valluri¹, Bogie Moore¹, Ying Cao¹, Vishala Chindalore³ and Bola Akinlade⁴, ¹Astellas Pharma Global Development, Inc., Northbrook, IL, ²Drug Metabolism Research Labs. Drug Discovery Research, Astellas Pharma Inc., Osaka, Japan, ³Pinnacle Research Group/Anniston Medical Clinic, Anniston, AL, ⁴Immunology Development, Astellas Pharma Global Development, Inc., Northbrook, IL
Background/Purpose: ASP015K is an oral Janus kinase (JAK) inhibitor with selectivity for JAK1/3 in development for treatment of rheumatoid arthritis (RA) and other autoimmune diseases.…
Abstract Number: 1697 • 2012 ACR/ARHP Annual Meeting
Meta-Analysis of Malignancies, Serious Infections, and Serious Adverse Events with Tofacitinib or Biologic Treatment in Rheumatoid Arthritis Clinical Trials
Sima Ahadieh¹, Tina Checchio¹, Thomas Tensfeldt¹, Jonathan French², Sriram Krishnaswami¹, Richard Riese³, Sujatha Menon¹, Mary G. Boy¹ and Jamie L. Geier⁴, ¹Pfizer Inc., Groton, CT, ²Metrum Research Institute, Tariffville, CT, ³Pfizer Inc, Groton, CT, ⁴Epidemiology, Pfizer Inc., New York, NY
Background/Purpose: Patients with rheumatoid arthritis (RA) experience adverse events (AEs) attributed to both the disease and its treatment. Tofacitinib is a novel oral Janus kinase…
Abstract Number: 2084 • 2012 ACR/ARHP Annual Meeting
ASP015K: A Novel JAK Inhibitor Demonstrated Potent Efficacy in Adjuvant-Induced Arthritis Model in Rats
Shunji Yamazaki¹, Masamichi Inami¹, Misato Ito¹, Yasutomo Fujii¹, Kaori Hanaoka¹, Kaoru Yamagami¹, Kenji Okuma¹, Yoshiaki Morita¹, Shohei Shirakami², Takayuki Inoue², Susumu Miyata³ and Yasuyuki Higashi¹, ¹Pharmacology Research Labs, Astellas Pharma Inc., Tsukuba, Japan, ²Chemistry Research Labs, Astellas Pharma Inc., Tsukuba, Japan, ³Research Planning & Administration, Astellas Pharma Inc., Tsukuba, Japan
Background/Purpose: The Janus kinase (JAK) family of enzymes plays a key role in cytokine signaling, which is involved in the pathogenic events of immune-mediated disorders…
Abstract Number: 2150 • 2012 ACR/ARHP Annual Meeting
Action of Tofacitinib Via Human Dendritic Cells
Satoshi Kubo¹, Kunihiro Yamaoka², Shigeru Iwata¹ and Yoshiya Tanaka¹, ¹First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: Tofacitinib, an oral Janus Kinase (JAK) inhibitor, has gathered attention in treatment of Rheumatoid arthritis (RA). Although JAKs are well known for its importance…
Abstract Number: 2326 • 2012 ACR/ARHP Annual Meeting
Discovery of a Highly Potent, Selective Reversible Covalent Inhibitor of JAK3 Kinase
Ronald J. Hill¹, Angelina Bisconte¹, J. Michael Bradshaw¹, Ken Brameld², Eun Ok Kim¹, Xiaoyan Li², Tim Owens², Erik Verner² and David M. Goldstein², ¹Biology, Principia Biopharma, South San Francisco, CA, ²Chemistry, Principia Biopharma
Background/Purpose: Targeting of the JAK-STAT pathway has been shown to be efficacious for treatment of patients with rheumatoid arthritis through the successful use of pan-JAK…
Abstract Number: 2485 • 2012 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor: Analyses of Efficacy and Safety of 10 versus 5mg Twice Daily in a Pooled Phase 3 and Long-Term Extension Rheumatoid Arthritis Population
S. Cohen¹, S. Krishnaswami², B. Benda³, R. Riese², M.G. Boy⁴, D. Gruben⁴, G. Wallenstein⁵, C. A. Mebus⁴, S. H. Zwillich² and J. D. Bradley⁶, ¹Metroplex Clinical Research Centre, Dallas, TX, ²Pfizer Inc., Groton, CT, ³Clinical Development & Medical Affairs, Pfizer Inc., Collegeville, PA, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Worldwide Pharmaceutical Development, Pfizer Inc., Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. Phase (P) 3 studies demonstrated…